Abiopharma

🔍 Carrai Phillip D (Executive)

Company: KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (KTOS)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Sold 5,200 shares of Common Stock at $63.4135 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 203,384.00 | transaction_form_type: 4 | Footnotes: F1, F3, F6
• Sold 1,200 shares of Common Stock at $64.1801 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 202,184.00 | transaction_form_type: 4 | Footnotes: F1, F4, F6
• Sold 100 shares of Common Stock at $64.97 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 202,084.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 20,000 shares of Common Stock at $63.1407 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 182,084.00 | transaction_form_type: 4 | Footnotes: F2, F5, F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: by trust | shares_owned_after: 46,644.00

Footnotes:

• F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 26, 2025.
• F2: Open market sale of Issuer's common stock made in accordance with Issuer's trading policies.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.95 to $63.935 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.95 to $64.67 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.945 to $63.47 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F6: Includes 1,232 shares purchased through Issuer's Employee Stock Purchase Plan and approximately 4,537 shares held through Issuer's 401(k) Plan.